Subtypes of humanized antibody against interleukin-6 receptor

What is this patent about?

’980 is related to the field of recombinant protein production and the characterization of monoclonal antibody variants. Specifically, it addresses the structural heterogeneity that occurs during the biosynthesis of humanized antibodies in host cells, where post-translational modifications can lead to multiple molecular subtypes within a single pharmaceutical batch.

The underlying idea behind ’980 is that specific C-terminal modifications to the heavy chain of the PM-1 antibody—specifically the loss of a terminal glycine and the subsequent amidation of the proline residue at position 447—result in distinct subtypes that maintain full biological potency. The invention recognizes that these amidated variants are not merely degradation products but functional isoforms that can be characterized and utilized in pharmaceutical compositions.

The claims of ’980 focus on two specific molecular architectures of the humanized PM-1 antibody targeting the interleukin-6 receptor. Subtype 1 is defined as a heterodimeric variant where one heavy chain retains the standard C-terminal glycine while the other ends in an amidated proline, whereas Subtype 2 is a homodimeric variant where both heavy chains are truncated and amidated at the proline-447 position.

In practice, these subtypes are generated during cell culture, particularly when using specific growth media such as those containing fish meat-derived peptones. The invention utilizes liquid chromatography and mass spectrometry to isolate and verify these structures, ensuring that the resulting pharmaceutical product is well-characterized. This level of structural detail is critical for meeting the stringent quality and consistency requirements for injectable biologic drugs.

This approach differs from prior methods by identifying and validating the therapeutic equivalence of these specific C-terminal isoforms. While traditional manufacturing might view such variations as impurities, ’980 demonstrates that these amidated subtypes retain identical antigen-binding and cell-growth inhibition properties as the native sequence, allowing for a more precise definition of the active ingredients in anti-IL-6R therapies.